Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051919 | 0.84 | OPRK1 (0.35) | MAOAADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL14288809 | 0.81 | TTR (0.50) | TTRCES1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL8711081 | 0.81 | ALDH1A1 (0.33) | MAOATTRL3MBTL1ADRA2AADRA2B | |
| SCHEMBL8715342 | 0.81 | TTR (0.32) | MAOATTRL3MBTL1ADRA2AADRA2B | |
| SCHEMBL14281169 | 0.76 | HTR2A (0.43) | ADRA2AADRA2BADRA2CSLC6A2HTR2C | |
| SCHEMBL14281159 | 0.74 | HDAC6 (0.32) | CES1ALDH1A1GAA | |
| SCHEMBL14281161 | 0.73 | — | — | |
| SCHEMBL9813161 | 0.73 | DRD2 (0.32) | L3MBTL1MEN1KMT2ADRD3ALDH1A1 | |
| SCHEMBL13636983 | 0.73 | — | — | |
| SCHEMBL4571020 | 0.73 | MAOA (0.60) | MAOATTRCES1L3MBTL1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247165-B2 | Anti-syneresis agents for fracturing operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-11 | — | — | US | claimed |
| US-20250051634-A1 | ANTI-SYNERESIS AGENTS FOR FRACTURING OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-02-13 | — | — | US | claimed |
| EP-2247687-B1 | COMPOSITIONS AND METHODS OF TREATING HIGH TEMPERATURE SUBTERRANEAN FORMATIONS | BAKER HUGHES A GE CO LLC (US) | 2018-07-25 | — | — | EP | claimed |
| US-9902786-B2 | Method for immediately terminating radical polymerizations, inhibitor solution, and use thereof | ALLESSA GMBH (DE) | 2018-02-27 | — | — | US | claimed |
| EP-2941443-B1 | METHOD FOR IMMEDIATELY TERMINATING RADICAL POLYMERIZATIONS, INHIBITOR SOLUTION, AND USE THEREOF | ALLESSA GMBH (DE) | 2017-02-15 | — | — | EP | claimed |
| EP-2166060-B1 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-08-10 | — | — | EP | claimed |
| EP-2085424-B2 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| US-20150337056-A1 | Method for Immediately Terminating Radical Polymerizations, Inhibitor Solution, and Use Thereof | ALLESSA GMBH (DE) | 2015-11-26 | — | — | US | claimed |
| US-7842741-B2 | Stabilized aqueous polymer compositions | ALLESSA CHEMIE GMBH (DE) | 2010-11-30 | — | — | US | claimed |
| EP-2085424-B1 | Stabilized aqueous polymer compositions | ALLESSA CHEMIE GMBH (DE) | 2010-08-25 | — | — | EP | claimed |
| US-20100075871-A1 | Stabilized aqueous polymer compositions and their use | TOUGAS HOLDING GMBH (DE) | 2010-03-25 | — | — | US | claimed |
| EP-2166060-A1 | Stabilized aqueous polymer compositions and their use | Allessa Chemie GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| EP-2085424-A1 | Stabilized aqueous polymer compositions | Allessa Chemie GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20090192055-A1 | Stabilized aqueous polymer compositions | TOUGAS HOLDING GMBH (DE) | 2009-07-30 | — | — | US | claimed |
| US-12247165-B2 | Anti-syneresis agents for fracturing operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20250075122-A1 | ADDITIVES TO PREVENT THERMAL THINNING IN POLYMER GEL SYSTEMS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250051634-A1 | ANTI-SYNERESIS AGENTS FOR FRACTURING OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| JP-2000080581-A | PITCH TROUBLE PREVENTION WITH ENZYME | NIPPON PAPER INDUSTRIES CO LTD | 2000-03-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | MAOA 3783/4885TTR 2409/4885CES1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.